Results 221 to 230 of about 299,239 (347)

DRUG REPURPOSING FOR TREATMENT OF COVID-19 PATIENTS

JOURNAL OF SUSTAINABILITY SCIENCE AND MANAGEMENT, 2021
MOHD YUSMAIDIE AZIZ, HISHAM ATAN EDINUR
openaire   +1 more source

Classification of Coronavirus (COVID-19) Treatments and Drugs Based on Mechanism of Action, Efficacy, and Safety

, 2020
Mahi Ravi, William M. Jackson
openalex   +2 more sources

Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint

, 2021
Marika Alborghetti, Gianmarco Bellucci, Antonietta Gentile, Chiara Calderoni, Ferdinando Nicoletti, Ruggero Capra, Marco Salvetti, Diego Centonze   +7 more
openalex   +2 more sources

Inhalable Artificial Polymeric Nucleases Degrading Neutrophil Extracellular Trap‐DNAs and Alleviating Pulmonary Fibrosis

Advanced Science, EarlyView.
Pulmonary fibrosis (PF) is promoted by NETs that induce fibroblast activation. PEG‐PIm, a polymeric artificial DNase is reported that efficiently degrades NET‐DNA via phosphodiester bond hydrolysis. Inhalation of PEG‐PIm in a mouse PF model prevents fibroblast activation and fibrosis progression, offering a promising therapeutic strategy for NET ...
Yibo Du, Chenxu Zhu, Ruifeng Wang, Shi Chen, Chuang Li, Defang OuYang, Lixin Liu, Yongming Chen   +7 more
wiley   +1 more source

The Pathophysiology of Repurposed Antiviral Drugs for treatment of COVID-19 Infection

, 2020
Adnan Haider, Muhammad Faheem, Sayed Babar Jamal, Muhammad Naeem, Atif Ali Khan Khalil, Raees Khan, Fazli Subhan   +6 more
openalex   +1 more source

Divergent Delivery and Expression Kinetics of Lipid and Polymeric Nanoparticles across mRNA Modalities

Advanced Science, EarlyView.
Self‐amplifying (saRNA), linear (linRNA), and circular (circRNA) mRNAs are compared under standardized conditions using lipid nanoparticles (LNPs) and pABOL polymer. saRNA achieved superior expression, while linRNA and circRNA performance varied based on untranslated region elements and delivery method.
Irafasha C. Casmil, Josh J. Friesen, Nuthan V. Bathula, Anneke Strumpel, Chia Hao Ho, Ilana Guez, Kristen Y. S. Kong, Andrew J. Varley, Shigeki J. Miyake‐Stoner, Parinaz Aliahmad, Nathaniel S. Wang, Andrew J. Geall, Anna K. Blakney   +12 more
wiley   +1 more source

Safety of Drugs Used in the Treatment of COVID-19

Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, 2021
Elif Baris, Mukaddes Gumustekin, M. Aylin Arici   +2 more
openaire   +1 more source

Pharmacokinetic Simulation of Optimal Lopinavir and Ritonavir Dose Combination for COVID-19: Boosting Lopinavir With Ritonavir. [PDF]

In Vivo
Nakamaru Y, Sako KI, Ide N, Matsuda Y, Yamashita F, Maeda T.   +5 more
europepmc   +1 more source

Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19

, 2021
Liusheng Wu, Yuzhen Zheng, Jixian Liu, Ruixing Luo, Dingwang Wu, Pengcheng Xu, Da Wu, Xiaoqiang Li   +7 more
openalex   +1 more source

Rapid and Ultra‐Sensitive SARS‐CoV‐2 Subgenomic RNA Detection Using Single‐Molecule With a Large Transistor‐SiMoT Bioelectronic Platform

Advanced Electronic Materials, EarlyView.
The single‐molecule with a large transistor‐SiMoT is proposed for the detection of the subgenomic RNA of SARS‐CoV‐2, achieving a diagnostic sensitivity of 98.0% and a specificity of 87.8%. The SiMoT technology, currently at TRL‐5, is suitable for point‐of‐care settings and delivers the result to the end user in 30 min.
Eleonora Macchia, Anna Maria D'Erchia, Mariapia Caputo, Angelica Bianco, Claudia Leoni, Francesca Intranuovo, Cecilia Scandurra, Lucia Sarcina, Cinzia Di Franco, Paolo Bollella, Gaetano Scamarcio, Luisa Torsi, Graziano Pesole   +12 more
wiley   +1 more source